Poster NumberPresenterPresentationAbstract
Clinical
1Matthew AkiyamaA Phylogenetic Analysis of HCV Transmission Among PWID on Opioid Agonist Therapy in the Prevail Study Abstract
2Maryam AlaviAn Intervention to Improve HCV Testing, Linkage to Care, and Treatment Among People Who Use Drugs in Tehran, Iran: The Enhance StudyAbstract
3Olga AnagnostouIs The Availability Of Direct Antiviral Agents (DDAS) Enough To Treat Chronic Hepatitis C (CHC) And Achieve HCV Elimination Among People Who Use Drugs (PWUD)? What Do The Real World Data Suggest?Abstract
4Tarik AsselahTreating the New Epidemic: Efficacy and Safety of Elbasvir/Grazoprevir (Ebr/Gzr) in People with Hepatitis C Virus (Hcv) Infection Aged 35 Years or YoungerAbstract
5Alison BoyleTreatment With Direct Acting Antivirals Leads To Increased Uptake Of Injecting Equipment Provision (Iep), And Low Rates Of Reinfection: Results From A Scottish CohortAbstract
6Jordan FranchevillePoor Adherence To Hepatocellular Carcinoma Screening In A Cohort Of Cirrhotic Patients After Hepatitis C Cure Abstract
7Stefan ChristensenHigh Cure Rates In A Real World Cohort Of HCV Infected Patients On Opioid Substitution Therapy (OST) Despite Alcohol And Cannabis Consumption - Data From The German Hepatitis C-Registry (DHC-R)Abstract
8Andrea BregenzerFeasibility, Outcome And Uptake Of Ifn-Based And IFN-Free DAA HCV-Treatment In OST Patients In Switzerland – The SAMMSU-CohortAbstract
9Brian ConwayElbasvir/Grazoprevir, Ledipasvir/Sofosbuvir And Velpatisvir/Sofosbuvir Therapy Among People Who Use Drugs (PWUD): Real World Experience Abstract
10Brian ConwayLoss To Follow-Up Among PWUD Receiving HCV Treatment: Predictors And Intervention StrategiesAbstract
11Eric CrownIntegrated Efficacy And Safety Of Glecaprevir/Pibrentasvir In Patients With Psychiatric DisordersAbstract
12David de GijselTelemedicine for the Treatment of Hepatitis C: A Systematic Review and Meta-AnalysisAbstract
13David de GijselLow Hepatitis C Treatment Rates Among Patients Screened As Inpatients At A Rural Academic Medical Center Abstract
14Benjamin EckhardtCan Hepatitis C Virus (HCV) Reinfection Be Predicted And Prevented Among People Who Currently Inject Drugs (PCID)? The Potential Importance Of Understanding And Intervening Upon Injection Networks To Achieve Sustained AviremiaAbstract
15Leanne Myers"How Do We Reach The Other 75% Of People With Untreated Chronic Hepatitis C In Australia?"Abstract
16Phillip ReadRecall Can Increase Treatment Uptake: An Audit Of Positive Hepatitis C PCR Tests At The Kirketon Road CentreAbstract
17Luca ForoghiPreliminary Results About HCV Care Cascade Among PWID In Rome Setting: “Una Regione Senza La C” ProjectAbstract
18Ravi JayantiChronic Hepatitis C Treatment Response With Direct-Acting Antivirals In Patients With Substance Abuse- A Community Hospital Based StudyAbstract
19Ravi JayantiDirect Acting Antivirals In HCV Mono-Infection Compared To HCV/HIV Co-Infection In Community Care Setting- A Real-World ExperienceAbstract
20Raphael SchubertInterim Results Of An Ongoing Project To Eradicate HCV In People Who Inject Drugs At Risk For Non-Adherence To Direct-Acting Antivirals In ViennaAbstract
21Grishma HirodeHigh Proportion Of Undiagnosed Hepatitis C Virus (HCV) Infection Among Persons Who Inject Drugs: A Community-Based Safety-Net Hospital ExperienceAbstract
22Julie HoleksaReversal Of Fibrosis After Successful HCV Treatment In People Who Inject Drugs (PWID)Abstract
23Julie HoleksaReal-Life Cohorts And The Impact Of Losses To Follow-Up (LTFU) On HCV Sustained Virologic Response (SVR) RatesAbstract
24Julie HoleksaLack Of Follow-Up After End Of Treatment And Recurrent Viremia Among PWUD Treated For HCV InfectionAbstract
25Eva JacksonFactors Influencing Engagement With A Multidisciplinary Incentivised Hepatitis C Program For Intravenous Substance UsersAbstract
26Martin KåbergEnhancing The Hepatitis C (HCV) Care Cascade For People Who Inject Drugs (PWID) At The Stockholm Needle Exchange – Results From Fibroscan Examinations And Hcv TreatmentAbstract
27John LambertHepcare Europe: Hepcheck; Point Of Care Hepatitis C Testing In Vulnerable Populations Abstract
28Phyllis LosikoffProviding Access To Hepatitis C Treatment Improves Adherence to Addiction Treatment In An Outpatient Addiction Treatment CenterAbstract
29Amy MalagutiReceiving Hepatitis C Treatment As A Couple: Romantic Partners’ Mutual Reduction Of Injecting Behaviour Frequency. Abstract
30Stefanie MaterniakDifferences In Sustained Virologic Response To Direct-Acting Antiviral Therapy For Chronic Hepatitis C By Sex – Results From The Canhepc Retrospective RegistryAbstract
31Marion SelfridgeDirect-Acting Antiviral Therapy For HCV Infection In People With Recent Injecting Drug Use Attending An Inner-City Community Health Centre In Victoria, Canada Abstract
32Lynn TaylorReal World Direct Acting Antiviral (DAA) Outcomes Among People Who Inject Drugs: Hepatitis C Real Options (HERO)Abstract
33Elisabetta TetiReal World Adherence To Direct-Acting Antivirals In A Cohort Of People Who Use Drugs In Rome, ItalyAbstract
34Murat YildirimNew Directly Acting Antiviral Therapy Of HCV Infected People Who Injected Drugs: Real Life Experience From TurkeyAbstract
35Kjersti UlsteinHigh Efficacy Of Direct-Acting Antiviral HCV Treatment Among People With Recent Injecting Drug Use: A Real-Life ExperienceAbstract
Global and Public Health
36Silvia BronsonA Screening Program For Hepatitis C Among Baby Boomers In The Northeast United States Has Revealed An Alarmingly High Prevalence Of Hcv Infection Among People Who Inject DrugsAbstract
37Françoise DesselleFirst Line Screening By Fibroscan (Transiant Elastography) In A Population At High Risk For HCV InfectionAbstract
38Stéphanie DominguezStrenghtening Patient's Pathway For A Better Hepatitis C Care In Most Vulnerable Populations: The HCV Parcours Projet In Ile De France (IDF)Abstract
39Kristin AlexiusdottirMarked Reduction In The Prevalence Of Hepatitis C Viremia In The Prison Setting During 2nd Year Of Traphepc (Treatment As Prevention For Hepatitis C) Program In IcelandAbstract
40Caroline GahrtonPrevalence of Viremic Hepatitis C Virus, Hepatitis B Virus or HIV Infection, and Vaccination Status among Swedish PrisonersAbstract
41Ilias GountasWithdrawn
42Matt HickmanThe Hepatitis C Pre-DAA Cascade Of Care For Persons Using Drug Services In England.Abstract
43Vivian HopeFactors Associated With Hepatitis C Testing Uptake Among People Who Inject Image And Performance Enhancing Drugs.Abstract
44Brendan JackaEpidemiology Of Injection Drug Use And Prevention Of Hcv Infection Among People Who Inject Drugs In Canada, 2011-2016Abstract
45John LambertThe Prevalence Of Chronic Untreated Hepatitis C Virus Infection And Associated Risk Factors In Irish Prisoners; A Cross Sectional StudyAbstract
46John LambertTen-Year Mortality Demonstrates That Opioid Substitute Patients, With High Alcohol Intake, Require Early Linkage To Hepatitis C (HCV) TreatmentAbstract
47Sarah LarneyGlobal Multi-Level Analysis Of Demographic, Behavioural And Ecological Factors Associated With HCV Antibody Prevalence In People Who Inject DrugsAbstract
48Andrea LombardHepatitis C Positive: Stigma And Drug Use ChallengesAbstract
49Rui MarinhoOrigin, Diversity And Transmission Dynamics Of Hepatitis C Virus Genotypes In PortugalAbstract
50Mojca MaticicPrevalence And Characteristics Of HCV Infection In People Who Use Drugs Managed At Low-Threshold Settings In Slovenia: Results From A National StudyAbstract
51Pedro Mateu-GelabertInjection Risk Behaviors And Hcv Infection Among Young Opioid Injectors In New York City: A Challenge For HCV EliminationAbstract
52Nanor MinoyanNot If, But Where: Socio-Spatial Injection Contexts And Binge Drug Injection In A Prospective Cohort Of People Who Inject Drugs In Montreal, CanadaAbstract
53Ryan BuchananRe-Setting The Target For Hepatitis C Micro-Elimination In An Isolated Uk PopulationAbstract
54Natasha MartinIs Hcv Elimination Among Hiv-Infected People Who Inject Drugs Possible Through Treating Hiv/Hcv Coinfection? A Modeling Analysis For Andalusia, SpainAbstract
55Julia EnkelmannHigh Prevalence Of Current And Past Hepatitis C Virus Infections Among New Injectors Found In A Cross-Sectional Study In Germany, 2011-2014: Missed Opportunities For Counselling And TestingAbstract
56Amine GhrabiInjecting Risk Behaviors And HCV Genotypes Distribution Among People Who Inject Drugs Attending A Syringe Service Program In Tunis, TunisiaAbstract
57Anne ØvrehusThe Impact Of High Risk Behaviors And Hepatitis C On Mortality In Drug Users. A Register Based Cohort Study On 5350 Persons Connected To Drug Use Treatment 1996-2014.Abstract
58Alisa PedranaEstimating Progression Through The Cascade Of Care Among Patients With Hepatitis C Infection In Victoria, Australia After The Introduction Of Direct-Acting AntiviralsAbstract
59Katherine Wagner¡Dale! ¡Vale!:  Tracking The HCV Epidemic In Young People Who Inject Drugs In New MexicoAbstract
60Andrew ScheibePrevalence Of Hepatitis C, B And HIV Among People Who Use Drugs In Three South African CitiesAbstract
61Nick ScottUpscaling Prevention To Control Hepatitis C As A Public Health Threat In TanzaniaAbstract
62Thomas SeylerWithdrawn
63Ida SperleBarriers To HCV Testing In Drug Treatment Services For People Who Inject DrugsAbstract
64Julian SureyMobile Community-Based Liver Health Assessment In Underserved Populations: The Hepcare Project Abstract
65Lara TavoschiECDC/EMCDDA Evidence-Based Guidance On Prevention And Control Of HCV In Prison Settings Abstract
66Elisabetta TetiHCV Seroprevalence And Risk Factors In A Cohort Of People Who Use Drugs Screened With Rapid Tests In Rome: The Hidden EpidemicAbstract
67Prem ThurairajahWithdrawn
68Magally Torres LeguizamonInventory And Strategies Of Development For Preventing, Screening And Monitoring Hepatitis C Among Drug UsersAbstract
69Adam TrickeyThe Contribution Of Injecting Drug Use To Hepatitis C Virus Transmission Globally, Regionally, And At Country Level: A Modelling StudyAbstract
70Daniela van SantenThree Decades Of Harm Reduction Programs In A Country With Liberal Drug Policies: Factors Associated With Its Uptake Among People Who Inject Drugs In AmsterdamAbstract
71April YoungRecruitment Methods For Epidemiologic Research On Hepatitis C Among Rural Young Adults Who Inject DrugsAbstract
Health Services
72Ryan BuchananThe Cost Effectiveness Of Community Pharmacy Dry Blood Spot Screening For Hepatitis C In A Rural Population Of People Who Inject DrugsAbstract
73Esther CroesHCV Elimination In Dutch PWUD? The 5 Steps Of The National Hepatitis PlanAbstract
74Sarah GanderHepatitis C Screening Program In Infants Born To High Risk MothersAbstract
75Cheng GongThe Association Between Delayed Return And Transfer Experience Among Methadone Maintenance Treatment Participants In Guangdong, China: A Retrospective Cohort StudyAbstract
76Emma HamiltonA Mixed Method Evaluation Of NHS Tayside’s Injecting Equipment Provision ServicesAbstract
77Mary Ellen HarrodLanguage Matters: The Development Of A Resource To Improve Treatment Access And Reduce Stigma In Drug And Alcohol Treatment Settings Through A Community Partnership ModelAbstract
78Valerie LaiChanges In Quality Of Life Scores Before And After Hepatitis C Treatment By Inner-City Primary Teams In Inner-City Community Health Clinics Abstract
79Yin LiuLimited Hepatitis C Treatment And Barriers For Injection Drugusers In Chinese Methadone Treatment Clinics: Comprehensive Hepatiti C Care Is Needed Abstract
80Alyssa MargesonDemographic And Socioeconomic Differences Among Hepatitis C Patients Seen In Community And Specialist Outpatient Care Settings In New Brunswick, CanadaAbstract
81Elisa MartróEstimation of the Cascade of HCV Testing, Care and Treatment Among Active PWID Who Attend Four Harm-Reduction Centers in Catalonia (HepCdetect II Study)Abstract
82Elisa MartróUniversal On-Site HCV-RNA Screening is Warranted Among Active PWID Who Attend Harm Reduction Centres in Catalonia, Spain (HepCdetect II Study)Abstract
83Daniel SmythHCV-Infected Youth Characteristics And Representation In The Canhepc Retrospective National RegistryAbstract
84Withdrawn
85Neal BelluzzoHepatitis C Virus (HCV) Screening In People Who Use Drugs (PWUD): What Your Patients Want You To KnowAbstract
86Shashi KapadiaHepatitis C Treatment Wanted Yet Not Received: Barriers To Receiving HCV Treatment Among People Who Inject Drugs Abstract
87Theodora OikonomouExcellent Efficacy of Direct Acting Antivirals (Daas) for the Treatment of Hepatitis C Among People Who Inject Drugs (Pwid): Experience From a Large Expertized Greek CenterAbstract
88Cláudia PereiraIntegration Of HCV Care In Harm Reduction SettingsAbstract
89Nadine KronfliInterventions To Increase Testing, Linkage To Care And Treatment Of Hepatitis C Virus (HCV) Among People In Prisons: A Systematic Review Abstract
90Xavier Major RocaAssessment Of Hepatitis C Treatment Access Barriers Among PWID In The Catalan Substance Abuse Treatment NetworkAbstract
91Tetiana SaliukLost Opportunities And Potential Of HCV Test And Treatment Among People Who Inject Drugs In UkraineAbstract
92Eilish ScallanHepatitis C knowledge and training among people working in the alcohol and other drugs sectorAbstract
93Sinead SheilsHealth Promotion; A Continuing Role For Peer Support Worker In Drug Health Service Liver ClinicAbstract
94Katherine WagnerNew Questions About HCV From A New GenerationAbstract
Models of Care
95Adrian AbagiuOutcomes For Chronic Viral Hepatitis Treatment And Control, 10 Years Data From The First Harm Reduction Approach Ost Center From BucharestAbstract
96Antoine BachelardSpecial Concern And Strategy For Optimizing Cascade Care Among Prisoners. The HCV “Parcours” Project In Ile De France (IDF)Abstract
97Tyler BartholomewWithdrawn
98Rob BielenHepatitis C Nurse As A Case Manager In People Who Inject Drugs Abstract
99Beverly EdwardsThe Development Of A Collaborative Model To Optimise Antiviral Treatment In Community Drug ServicesAbstract
100Margaret Bourke Treatment Of Hepatitis C In A Community Based Opioid Substitution (OST) ClinicAbstract
101Christopher ByrnePharmacological Monitoring Of Participants Undergoing DAATreatment For Hepatitis C Infection In Nhs Tayside: Concomitant Medications Of People Who Inject Drugs Participating In The Superdot-C TrialAbstract
102Rui Miguel Coimbra MoraisC+, Be+, Be Your Rights – To End (Once And For All) With Hepatitis C Among Drug Users – An Example Of Community MobilizationAbstract
103Pauline DundasRe- Engaging PWID To Hepatitis C Care And Treatment In The North East Of ScotlandAbstract
104Dennaye FuchsExpanding Access To Hepatitis C Care In Community And Correctional Settings Via Non-Traditional Models In Saskatchewan, CanadaAbstract
105Stephen BarclayIntroduction Of A Combined OST/Advanced Fibrosis Community Clinic Results In High Engagement With A Cohort Of Patients With Previous Non Attendance At Hospital Appointments.Abstract
106Erika CastroHepatitis C treatment and Linkage to Care in Patients with Mental Illness who use Drugs: a Core Team Network Abstract
107Brendan HarneyEvaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, AustraliaAbstract
108Ronni MarksModel Addressing Hepatitis C- An Epidemic That Impacts PWIDAbstract
109Mary Ellen HarrodPeer Led Harm Reduction Service Delivers Significantly Better Outcomes In Hepatitis C Prevention And TreatmentAbstract
110Sarah InglisTowards The Microelimination Of HCV In Tayside, ScotlandAbstract
111Eva Jackson“Positively Hep” – A Multidisciplinary Incentivised Hepatitis C Program For Disadvantaged CommunitiesAbstract
112Nathalie KraichetteRural Environment, Breaking Distances To Care – Go Towards To Bring ToAbstract
113John LambertSeek And Treat; A Dublin Community Based Peer Facilitated Screening ProjectAbstract
114John LambertTreatment Of Hepatitis C In The Homeless Drug Using Population: An Innovative Shared Care Approach Removing Barriers To AccessAbstract
115Sara LamondSharing Hepatitis C Care can it work between primary and secondary services? Abstract
116Kim MacbethSuccessful Treatment Of Hepatitis C In A Dedicated Homeless GP Practice Using A Multidisciplinary ApproachAbstract
117Xavier Major RocaEvaluation Of An HCV Awareness-Raising And Testing Intervention In PWIDAbstract
118Lee MiddletonPrioritised Annual Hepatitis C Testing Drives In Drug Recovery Services Show Acceptability And Effectiveness Of TestingAbstract
119Lee MiddletonCombined Drug Recovery And Hepatitis C Treatment Clinic Leads To More Effective Engagement Than Traditional Care Model.Abstract
120Sandi MitchellWorking Collaboratively To Increase Hcv Testing And Treatment Abstract
121Alberto MoriggiaFrom Analysis To Social Innovation. The Aging Process Of People Who Use Drugs In Opioid Substitution Treatment: Development Of Innovative Care Scenarios And Training Programs For Social And Health ProfessionalsAbstract
122Alberto MoriggiaPursuing Micro-Elimination Of HCV Among PWID In An OST Clinic In Southern Switzerland: The Implementation Of DAA Therapy Through An Interdisciplinary ApproachAbstract
123Alberto MoriggiaDrug And Alcohol Use During HCV Treatment In The Real Life Among PWID In Southern SwitzerlandAbstract
124Cyril OlaizolaTest And Treat : 6 Years Of HCV Rapid Testing Among Drug Users In The Bayonne Area (France)Abstract
125Mary ParkerProject INTACCT (Integrated Community Hepatitis C Treatment)Abstract
126Noreen ReedLiver Health Event: De-Stigmatizing Hepatitis C To Enhance Screening And Linkage To Care In Indigenous CommunitiesAbstract
127Noreen ReedCommunity Led Hepatitis C Treatment Amongst People With Active Injection Drug Use In An Indigenous Community In CanadaAbstract
128Vratislav Rehak20 Years Of Evolution Of The Comprehensive Model Of Care For PWID To Enhance HCV Treatment Uptake And OutcomeAbstract
129Andre Jean RemyHospital Zero Hepatitis For Drug Users : Easy And Useful!Abstract
130Anne-Marie Roque-AfonsoFeasibility Of A Global Out Of Wall Assessment Of Hepatitis C Liver Disease In Drug Center (Service)Abstract
131Pablo RyanScreening For HCV With Dried Blood Spot Test In Active Drug Users. Evaluation Of Magnitude Before InterventionAbstract
132Nathan RyderImproving Access To Hepatitis C Treatment For People Currently Injecting Drugs, A Sexual Health Clinic Model Of CareAbstract
133Sinan FundaIdentification, Assessment And Management Of Hepatitis C Virus (HCV) And Delivering Direct Acting Antiviral (DAA) Treatment In Outreach SettingAbstract
134Julian SureyVideo Observer Treatment For Hepatitis C Patients - Improving Adherence And Outcomes: Hepcare EuropeAbstract
135Julian SureyHepfriend: Peer Support And Community Engagement In Underserved Populations With Hepatitis C In The UK, Ireland, Romania And Spain As Part Of The Hepcare ProgrammeAbstract
136Vana SypsaA Pilot Program Of Screening And Linkage To Care For Hepatitis C In A Greek PrisonAbstract
137Prem ThurairajahWithdrawn
138Martin TournadreHCV: From Screening To Cure, A Broad Partnership Within A Tough BackgroundAbstract
139Stacey TrooskinC Change: Philadelphia’s Plan To Eliminate Hepatitis C Among People Who Use Injection DrugsAbstract
140Oliver WehrliThe Swiss Hepatitis C Association (SHCA)Abstract
141Tessa WindelinckxExpertC, A Pilot In Building A Care Cascade From The Ground UpAbstract
142Karolina ZakrzewskaHepatitis C Cascade Of Care Among People Who Inject Drugs In Poland: Gaps Both At Testing And Linkage To Care LevelsAbstract
143Julie TremblayWithdrawn
Social Science
144Maria DonatelliSnapshot Of Frontline Perspectives On Hepatitis C Services For Most-At-Risk Populations In Middle Income Countries: Informing Progress And Response Toward 2030 Elimination TargetsAbstract
145Joseph DoylePast Experiences Of Stigma Shaping Present Perceptions Of Healthcare Among People Who Inject Drugs Living With Hepatitis CAbstract
146Steven KurtzHAV/ HBV/ HCVPrevalence, Risk Factors, And Hav/ Hbv Vaccine Uptake Among At-Risk Men Who Have Sex With Men (MSM)Abstract
147Kari Lancaster“Towards Eliminating Viral Hepatitis”: Examining The Productive Capacity And Constitutive Effects Of Global Policy On Hepatitis C EliminationAbstract